Bioxodes to present first-in-class drug candidate BIOX-101 for hemorrhagic stroke to investors and pharmaceutical community in range of conferences
February 20, 2024
Gosselies, Belgium
About
Bioxodes
Bioxodes’ innovative pipeline includes a clinical-stage program for the prevention of thrombosis and neuroinflammation in patients with an intracerebral hemorrhage (ICH).
Neuroinflammation plays a critical role in the neurologic decline of ICH patients. BIOX-101 (Ir-CPI), the lead drug candidate of this program, exhibits a unique mechanism of action by targeting coagulation factors (FXIIa & FXIa) and neutrophils, key driver components of the neuroinflammatory process. BIOX-101 prevents blood clot formation without increasing the bleeding risk — a major asset in ICH patients — due to the specific coagulation factors targeted by this compound.
In parallel, Bioxodes is developing a pipeline of drug candidates with the objectives to treat chronic thrombo-inflammatory and inflammatory diseases. The goal is to leverage the activity of BIOX-101 against neutrophil activation and neutrophil extracellular trap (NET) formation.
Our innovative pipeline includes a clinical-stage program with BIOX-101 (Ir-CPI) for the prevention of thrombosis and neuroinflammation in hemorrhagic stroke patients. Currently, our Phase IIa program is underway, aiming to gather safety data and initial evidence of efficacy in patients with ICH.
video testimonial
Prof Robin Lemmens, a world-renowned stroke expert, is the lead investigator of the current Phase 2a trial for BIOX-101 (Ir-CPI).
“Stroke is worldwide one of the main causes for mortality,” he says in this video. “We are really in need to find medication hear to try and improve their prognosis.” Professor Lemmens, the head of the stroke unit at the University Hospital Leuven (Belgium), was speaking at an investor event Bioxodes had organized in Zurich, in February 2024.
Product
All products-
![]()
Ir-CPI
Our first-in-class drug candidate with a unique mechanism of action on neutrophils and coagulation factors (FXIa and FXIIa).
Read more -
![]()
Pipeline
Bioxodes is building an innovative pipeline with drug candidates for the prevention of thrombo-inflammatory and inflammatory diseases.
Read More -
![]()
Clinical trials
Clinical trials are being conducted to assess the safety and efficacy of Ir-CPI with a primary focus on hemorrhagic stroke.
Read More
Advisory Board
All Key Opinion Leaders-
Read more
Robin Lemmens , M.D.
Leuven, Belgium
-
Read more
Rustam Al-Shahi Salman , MA MB BChir PhD FRCP Edin FHEA FESO
Edinburgh, United Kingdom
-
Read more
Ashkan Shoamanesh , M.D.
Hamilton, Canada
-
Read more
Matthias Endres , M.D.
Berlin, Germany
-
Read more
David Seiffge , M.D.
Bern, Switzerland
-
Read more
Cedric Hermans , M.D, Ph.D, FRCP (Lon, Edin)
Brussels, Belgium
-
Read more
Thomas Lecompte , M.D
Geneva, Switzerland
-
Read more
Denis Vivien , Ph.D
Caen, France
Recents News
Bioxodes closes €12 million in Series A funding round
November 21, 2023
Gosselies, Belgium
Funding will enable Bioxodes to continue clinical development of drug candidate for patients with intracerebral hemorrhage. Recruitment of first patient for phase IIa proof-of-concept clinical trial due before end of Q4, 2023
BioEurope Fall 2023
November 06, 2023
Munich, Germany
Bioxodes will be part of BioEurope Fall, our CEO Marc Dechamps will be on site for partnering meetings.
HealthTech Innovation Days #5
October 24, 2023
Paris, France
Bioxodes will be present at the 5th Edition of the HealthTech Innovation Days
Investors
Invest in us
Bioxodes is a Belgian private company, founded in 2013. The Company has received fundings from both the public and private investors.
